Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.

PURPOSE To examine the relationship between the density of tumor-infiltrating T cell subpopulations and the pathological response to induction chemoradiotherapy (CRT) in patients with locally advanced NSCLC, and to assess the impact of T cell density on patient prognosis. METHODS A total of 64 patients with c-stages IIA-IIIB NSCLC who underwent induction CRT followed by R0 surgery were enrolled. Tumor-infiltrating T cells expressing either FOXP3 or CD8 were detected by immunohistochemical staining. RESULTS Mean numbers of tumor-infiltrating FOXP3+ T cells were 39.9 for patients with minor pathological responses (n = 9), 18.4 for those with major pathological responses (n = 25), and 12.9 for those with complete pathological responses (n = 30; P <0.001). The number of CD8+ T cells was not associated with pathological responses. Patients with lower FOXP3+ T cell densities showed better survival, although the difference was not statistically significant. CONCLUSION Our study demonstrated that the density of tumor-infiltrating FOXP3+ T cells indicated the degree of response for induction CRT and prognosis in patients treated with trimodality therapy for locally advanced NSCLC, suggesting that FOXP3+ T cells may be target for adjunct immunotherapy.

[1]  J. Matsumoto,et al.  Novel aspects of preoperative chemoradiation therapy improving anti‐tumor immunity in pancreatic cancer , 2013, Cancer science.

[2]  R. G. van der Most,et al.  Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies , 2012, British Journal of Cancer.

[3]  S. Toyooka,et al.  Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. , 2012, Interactive cardiovascular and thoracic surgery.

[4]  P. Granone,et al.  Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. , 2012, The Annals of thoracic surgery.

[5]  R. deLeeuw,et al.  The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.

[6]  P. Granone,et al.  Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  C. Coutant,et al.  In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival , 2011, The Journal of pathology.

[8]  M. Liptay,et al.  Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. , 2011, The Annals of thoracic surgery.

[9]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[10]  R. Stahel,et al.  Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. , 2010, The Journal of thoracic and cardiovascular surgery.

[11]  K. Shimizu,et al.  Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  R. Fimmers,et al.  Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma , 2010, Cancer Immunology, Immunotherapy.

[13]  C. Dooms,et al.  Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[15]  N. Funata,et al.  A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. , 2009, Oncology reports.

[16]  E. Ruffini,et al.  Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. , 2009, The Annals of thoracic surgery.

[17]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[18]  W. Hilgers,et al.  Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[20]  A. Fattorossi,et al.  Neuropilin‐1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer , 2008, Immunology.

[21]  T. Okamoto,et al.  Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.

[22]  Kenji Suzuki,et al.  How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer , 2007, British Journal of Cancer.

[23]  V. Rusch,et al.  Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Oshikiri,et al.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.

[25]  K. Kiura,et al.  Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer , 2004, British Journal of Cancer.

[26]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.

[27]  Koichi Yamazaki,et al.  CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non‐small cell lung cancers , 2003, Cancer science.

[28]  D. Speiser,et al.  Human CD8+ T cells expressing HLA‐DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells , 2001, European journal of immunology.

[29]  H. Ohtani,et al.  Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. , 2000, The Tohoku journal of experimental medicine.

[30]  U. Pastorino,et al.  Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial , 1999, British Journal of Cancer.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.